Podcasts about mbchb

Idiopathic intracranial hypertension (IIH), a condition of increased intracranial pressure (ICP), causes debilitating headaches and, in some, visual loss. The visual defects are often in the periphery and not appreciated by the patient until advanced; therefore, monitoring visual function with serial examinations and visual fields is essential. In this episode, Kait Nevel, MD speaks with John J. Chen, MD, PhD, and Susan P. Mollan, MBChB, PhD, FRCOphth, authors of the article “Treatment and Monitoring of Idiopathic Intracranial Hypertension” in the Continuum® June 2025 Disorders of CSF Dynamics issue. Dr. Nevel is a Continuum® Audio interviewer and a neurologist and neuro-oncologist at Indiana University School of Medicine in Indianapolis, Indiana. Dr. Chen is a professor of ophthalmology and neurology at the Mayo Clinic in Rochester, Minnesota. Dr. Mollan is an honorary professor of metabolism and systems science in the department of neuro-ophthalmology at University Hospitals Birmingham in Birmingham, United Kingdom. Additional Resources Read the article: Treatment and Monitoring of Idiopathic Intracranial Hypertension Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @IUneurodocmom Guests: @chenmayo, @DrMollan Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Nevel: Hello, this is Dr Kate Nevel. Today, I'm interviewing Drs John Chen and Susan Mollan about their article on treatment and monitoring of idiopathic intracranial hypertension, which appears in the June 2025 Continuum issue on disorders of CSF dynamics. Drs Chen and Mollan, welcome to the podcast. And please, could you introduce yourselves to the audience? Dr Chen: Hello, everyone. I'm John Chen, one of the neuro-ophthalmologists at the Mayo Clinic. Thanks for having us here. Dr Mollan: Yeah, it's great to be with you here. I'm Susan Mollan. I'm a consultant neuro-ophthalmologist in Birmingham, England. Dr Nevel: Wonderful. So great to have you both here today, and our listeners. To start us off, talking about your article, can you share with us what you think is the most important takeaway from your article for the practicing neurologist out there? Dr Chen: Yeah, so our article talked about the treatment and monitoring of IIH. And I think one takeaway point is, IIH is becoming much more prevalent now that there's this worldwide obesity epidemic with obesity having- essentially being the largest risk factor for IIH other than female. It's really important to monitor vision because vision loss is often peripheral vision loss at first, which the patient may be completely unaware of. And so, it's important to pair up with an ophthalmologist so you can monitor the papilledema of the visual fields and make sure they don't get permanent vision loss. And in the article, we also talk about- there's been changes in the treatment of severe IIH, where traditionally, we used VP shunts; but there's been a trend toward using more venous sinus stenting in addition to the traditional surgeries. Dr Nevel: Great, thank you. I think probably most of our listeners or a lot of neurologists out there have a pretty good understanding of kind of the basics of the IIH. But can you kind of just go over a few key characteristics of IIH, and maybe some things that are less commonly known or things that are maybe just been kind of better understood over the past decade, perhaps? Dr Mollan: Yes, certainly. I think, as Dr Chen said, it's because this condition is becoming more prevalent, people recognize it. I think it's- we like to go back to the diagnostic criteria so that we're making a very accurate diagnosis. So, the patients may come in to the emergency room with, say, papilledema that's been identified elsewhere or crashing headaches. And it's important to go through that sort of diagnostic pathway, taking a blood pressure, taking a full blood count to make sure the patient is anemic, and then moving forward with that confirmation of papilledema into urgent neuroimaging, whether it's CT or MRI, but including venography to exclude a venous sinus thrombosis. And then if you have no structural lesion that's causing the raised ICP, it's moving forward with your lumbar puncture and carefully checking those pressures. But the patients may not only have crashing headache, they often have pulsatile tinnitus and neck pain. I think some of the features that we're now recognizing is the systemic metabolic effects that are unique to IIH. And so, there's an increased risk of cardiometabolic disease that's over and above what is conferred by obesity. Also, our patients have a sort of maternal health burden where they get impaired fertility, gestational diabetes and preeclampsia. And there's also an associated mental health burden, amongst other things. So we're really starting to understand the spectrum of the disease a bit more. Dr Nevel: Yeah, thank you for that. And that really struck me in your article, how important it is to be aware of those things so that we're making sure that we're managing our whole patient and connecting them with the appropriate providers for some of those other issues that may be associated. For the practicing neurologist out there without all the neuro-ophthalmology equipment, if you will, what should our bedside exam focus on to help us get maybe an early but accurate picture of the patient's visual function when we suspect IIH to be at play, perhaps before they can get in with the neuro-ophthalmologist? Dr Chen: Yeah, I think at the bedside you can still check visual acuity and confrontational visual fields, you know, with finger counting. Of course, you have to know that those are, kind of, crude kind of ways of screening. With papilledema, oftentimes the visual acuity is intact. And the confrontational visual fields aren't as sensitive as automated perimetry. Another important thing will be to do your direct ophthalmoscope and look at the amount of papilledema. If it's grade one or two papilledema on the more mild side, it's actually not vision threatening. It's the higher degrees of papilledema that can cause rapid vision loss. And so, if you look in and you see grade one papilledema, obviously you need to do the full workup, the MRI, MRV, lumbar puncture. But in terms of rapidly getting to an ophthalmologist to screen for vision loss, it's not going to be as important because you're not going to have vision loss at that low grade. If you look in and you see this rip-roaring papilledema, grade five papilledema, that patient is going to be at very severe risk of vision loss. So, I think that exam, looking at the optic nerve can be very helpful. And of course, talking to the patient about symptoms; is there decreased vision Is there double vision from a sixth nerve palsy? Are there transient visual obscurations which would indicate at least a higher degree of papilledema? That'd be helpful as well. Dr Nevel: Great, thank you. And when the patient does get in with a neuro-ophthalmologist, you talk in your article and, of course, in clinical practice, how OCT testing is important to monitor in this condition. Can you provide for the listeners the definition of OCT and how it plays a role in monitoring patients with IIH? Dr Mollan: Sure. So, OCT is short for optical coherence tomography imaging, and really the eye has been at the forefront of OCT alone. Our sort of cardiology colleagues are catching up on the imaging of blood vessels. But what it allows us to do is give us really good cross-sectional, anatomical-level changes that we can see both in the retina and also at the optic nerve head. And it gives us some really good measurements. It's not so good at sort of saying, is this definitely papilledema or not? That sort of lower end of disc elevation. But it is very good at ruling out what we call the pseudopapilledema. So, things like drusens or these other little masses we find underneath the optic nerve head. But in terms of monitoring, because we can longitudinally take these images and the reproducibility is pretty good at the optic nerve head, it allows us to see whether there's direct changes: either the papilledema getting worse or the papilledema getting better at the optic nerve head. It also gives us some indication of what's going on in the ganglion cell layer complex. And that can be helpful when we're thinking about sort of looking at structure versus function. So, ophthalmologists in general, we love OCT; and we spend much more time nowadays looking at the OCT than we really do the back of the eye. And it's just become critical for patients with papilledema to be able to be very accurate from visit to visit to see what's changing. Dr Nevel: How do you determine how frequently somebody needs to see the neuro-ophthalmologist with IIH and how often they need that OCT evaluation? Dr Chen: Once the diagnosis of IIH is made, how often they need to be seen and how frequent they need to be seen depends on the degree of papilledema. And again, OCT is really nice. You can quantify it and then different providers can actually use the same OCT numbers, which is super helpful. But again, if it's grade three papilledema or higher, or article thickness of 200 or higher, I tend to follow them a little bit more closely, trying to treat them more aggressively. Try to get the papilledema down into a safer zone. If it's grade one or two papilledema, we see them less frequently. So, my first visit might be three months out. They come with grade five papilledema, I'm seeing them within a few days to make sure that's papilledema's come down quickly because we're trying to decide, are they going to need surgery or not? Dr Nevel: Yeah, great. And that's a nice segue into talking a little bit about how we treat patients with IIH after the diagnosis is confirmed. And I'd like to just point out you have a very lovely figure in your article---Figure 5-6,---that I'd like to direct our listeners to read your article and check out that figure, which is kind of an algorithm on how we think about the various treatment options for patients who have IIH, which seems to rely a lot on the degree of presence of papilledema and the presence of vision disturbance. Could you maybe walk us through a little bit about how you think about the different treatment options for patients with IIH and when more urgent surgical intervention might be indicated? Dr Mollan: Yeah, sure. We always find it quite hard in any medical specialty to write these kind of flow diagrams because it's really an individual we're looking at. But these are kind of what we'd say is “broad brushstrokes” into those patients that we worry about, sort of, red disease in those patients, more amber disease. Now obviously, even those patients that may not have severe papilledema, they may have crashing headaches. So, they may be an urgent referral themselves because of that. And so, it's nice to try and work out which end of the spectrum you're working with. If we think of the papilledema, Dr Chen's already laid out the sort of lower end of the prison's scale---our grades one, our grades two---that we're less anxious about. And those patients, we would definitely be having discussions about medical management, which includes acetazolamide therapy; but also thinking about weight management. And it may well be that we talk a little bit further about weight management, but I think it's helpful to sort of coach those conversations after you've made a definite diagnosis. And then laying out the risk that's caused, potentially, the IIH in an individual. And then having a sort of open conversation with them about what changes they can have in their lifestyle alongside thinking about medical therapy. There's some patients with very low levels of papilledema that we decide not to put on medicines initially. As patients progress up that papilledema grade, we're definitely thinking about medical therapy. And our first line from the IIH treatment trial would be using acetazolamide, but we need to be thinking about using appropriate dosing. So, a lot of the patients that I see can be sent to me with very low doses that may be inappropriate for that person. In the IIHTT they used up to four grams daily in a divided dose. And you do need to counsel your patients when you're putting them on acetazolamide because of the side effects. You've got quite a nice table in this article about the side effects. I think if you get the patient on board, that they understand that they will experience side effects, that is helpful because they will expect it, and then possibly tolerate it a bit better. Moving through to that area where we're more anxious, that visual-threatening papilledema. As Dr Chen said, it's sort of like you look in and it's sort of “blood and thunder” in there. And you need to be getting on and encouraging the ophthalmologist to get a formal assessment of the visual field. It's very difficult to determine exactly the level at which- and we talk about the mean deviation in a lot of our research studies. But in general, it's a combination of things: the patient's journey to get to you, their symptoms, what's going on with the visual field, but what's also happening at the OCT. So, we look in and we see that fluid is seeping towards the fovea. We get very anxious, and those patients may not even have enough time for a rapid escalation of acetazolamide. It may well be at the first presentation, which we would term, like, fulminant; that we'd be thinking about surgical intervention. And I think before I stop, the other thing to say is, the surgical landscape is really changing. So, we're having some good studies coming out in terms of stenting. And so, there is a sort of bracket where it may well be that we are thinking about neuroradiological intervention in an earlier case. They may not quite be at that visual-threatening stage, but they may be resistant to medical treatments. Dr Nevel: Thank you for that. What do you think is a potential pitfall or a mistake to avoid, if you will, in the management of patients with IIH? Dr Chen: I think it's- in terms of pitfalls, I think the potential pitfalls I've seen are essentially patients where we don't necessarily create a good patient physician relationship. Where they don't have buy-ins on the treatment, they don't have buy-ins to come back, and they're lost to follow-up. And these patients can be dangerous, because they could have vision threatening papilledema and if not getting the appropriate treatment---and if they're not monitoring the vision---this can lead to poor outcomes. So, I've definitely seen that happen. As Dr Mollan said, you really have to tell them about the side effects from the medications. If you just take acetazolamide, letting them know the paresthesias and the changes in taste and some of these other side effects, they're going to immediately stop the medication. Again, and these medications do work, proven in the IIH treatment trial. So again, I think that patient-physician relationship is very important to make sure they have appropriate follow up. Dr Nevel: The topic of weight loss in this patient population can be tricky, and I know I talked with Susie in a prior interview about how to approach this topic with our patients in a sensitive and compassionate manner. Once this topic is broached, I find many patients are looking for advice on strategies for weight loss, or potentially medications or other interventions. How do you prioritize or think about the different weight loss strategies or treatments with your patients, and how do you think about the way that you recommend these different treatments or not? Dr Mollan: Yeah. I think that's a really great question because we sort of stray here into a specialty that we have not been trained in. One thing I definitely ask my patients: if they've been on a weight loss journey before, and what's worked for them and what's not worked for them. And within our different healthcare systems, we have access to different tiers of weight management approaches. But for the person sitting in front of me, that possibly there may be a long journey to access more professional care, it's about understanding. iIs there things that are free, such as, we have some apps in the National Health Service which are weight management applications where they can actually just start putting in their calories, their daily calorie intake. And those apps can be quite helpful and guiding in terms of targeting areas, but also informing the patient of what types of foods to avoid in their diet and what types of foods to include in their diet. And with some of the programs that are completely complementary, they also sometimes add on things about exercise. But I think it is a really difficult thing to manage as, say, an ophthalmologist or a neurologist, mainly because it's not our area of expertise. And I think we've all got to find, in our local hospitals and healthcare systems, those pathways where the patients may be able to access nutritional support, and sort of behavioral lifestyle therapy support, all the way through to the new medications for weight loss; and also for some people, bariatric surgery pathways. It's a tricky topic. Dr Nevel: So how should we counsel our patients about what to expect in the future in terms of visual outcomes? Dr Chen: I think a lot of that depends on the degree of papilledema when they present. If a patient comes in with grade five papilledema, that fulminant IIH that Dr Mollan had mentioned, these patients can have very severe vision loss. And even if we treat them very aggressively with high-dose medications and urgent surgical interventions, sometimes they can have permanent vision loss. And so, we counsel them that, you know, there's a strong chance that they're going to have a good amount of vision loss. But some patients, we're very surprised and we get a lot of vision back. So, we kind of set expectations, but we're cautiously optimistic that we can get vision back. If a patient presents with more mild papilledema like grade one or two papilledema, they're most likely not going to have any permanent vision loss as long as we're treating them, we're monitoring their vision, they're coming to their follow-ups. They tend to do very well from a vision perspective. Dr Nevel: That's great, thank you. And you know, ties into what you said earlier about really making sure that, you know, we create good- as with any patient, but good physician-patient relationships so that they, you know, trust us and they come to follow up so we can really monitor their vision appropriately. What do you think is going on in research in this area that's exciting? What do you think one of the next breakthroughs or thing that we need to understand the most about treatment and monitoring of IIH? Dr Chen: I think surgically, venous sinus stenting is going to probably take over the bulk of surgeries. We still need that randomized clinical trial, but we have some amazing outcomes with venous sinus stenting. And there's many efforts on randomized clinical trials for venous sinus stenting. So we'll have those results soon. From a medical standpoint, Dr Mollan can actually say, actually, more about this. Dr Mollan: I completely agree. The GLP-1 receptor agonists, the twofold prong approach: one is the weight loss where these patients, you know, have significant weight loss to put their disease into remission; and the other side of it is whether certain GLP-1s have the ability to reduce intracranial pressure. So, a phase 2 study that we undertook here in Birmingham did show that we were able to reduce intracranial pressure, but we don't think it's a class effect. So, I think the sort of big breakthrough will be looking at novel therapies like xenotide and other drugs that, say, work on the proximal kidney tubule. Are they able to reduce intracranial pressure directly? And I think we are on the cusp of a real breakthrough for this disease. Dr Nevel: Great. Thank you so much for chatting with me today. And I really learned a lot, appreciated the opportunity. I hope our listeners learned something today, too. So again, today I've been interviewing Drs John Chen and Susan Mollan about their article on treatment and monitoring of idiopathic intracranial hypertension, which appears in the most recent issue of Continuum on disorders of CSF dynamics. Be sure to check out Continuum Audio episodes from this and other issues. And thank you to our listeners for joining us today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AZC865. CME credit will be available until 19 June 2026.Navigating the Layers of Complexity in R/R B-Cell Cancers: From Clinical Prognosis to Emerging Therapeutic Prospects in CLL/SLL, MCL, and DLBCL In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AZC865. CME credit will be available until 19 June 2026.Navigating the Layers of Complexity in R/R B-Cell Cancers: From Clinical Prognosis to Emerging Therapeutic Prospects in CLL/SLL, MCL, and DLBCL In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.Disclosure information is available at the beginning of the video presentation.

The Faculty Factory podcast is back this week with a deep exploration of academic promotions for clinicians as we interview Anne Walling, MB, ChB, who has written extensively about the topic. Her writings are based on her years of practical on-the-job experience with faculty. Dr. Walling is a professor emerita at the University of Kansas School of Medicine-Wichita in Wichita, Kansas and is the author of Academic Promotion for Clinicians: A Practical Guide to Promotion and Tenure in Medical Schools. She joins our show this week as a first-time guest to discuss the second edition of this book, along with exploring a variety of aspects related to promotions in academic medicine from many different angles. You can learn more about her book here: https://link.springer.com/book/10.1007/978-3-031-84036-4

Interview with Michael McDermott, MBChB, author of CT Angiography, Healthy Lifestyle Behaviors, and Preventive Therapy: A Nested Substudy of the SCOT-HEART 2 Randomized Clinical Trial, and Pamela S. Douglas, MD, author of The Last Mile in Prevention—Can Coronary CT Angiography Help? Hosted by Ann Marie Navar, MD, PhD. Related Content: CT Angiography, Healthy Lifestyle Behaviors, and Preventive Therapy The Last Mile in Prevention—Can Coronary CT Angiography Help?

Interview with Michael McDermott, MBChB, author of CT Angiography, Healthy Lifestyle Behaviors, and Preventive Therapy: A Nested Substudy of the SCOT-HEART 2 Randomized Clinical Trial, and Pamela S. Douglas, MD, author of The Last Mile in Prevention—Can Coronary CT Angiography Help? Hosted by Ann Marie Navar, MD, PhD. Related Content: CT Angiography, Healthy Lifestyle Behaviors, and Preventive Therapy The Last Mile in Prevention—Can Coronary CT Angiography Help?

Join hosts Nidhi Madan, MD; Prashant Nagpal, MD, FSCCT; Jill Jacobs, MD, MS-HQSM, FSCCT and Cristina Fuss, MD, PhD, FSCCT as they take a deep dive into featured articles in the March – April 2025 issue of the Journal of Cardiovascular Computed Tomography (JCCT). Our hosts chat with Jonathan Weir McCall, MBChB, PhD, FRCR, FSCCT; Tilman Emrich, MD; Akos Varga-Szemes, MD, PhD; Emese Zsarnoczay, MD; David Wilson, PhD and Juhwan Lee, PhD . This episode will explore:A new business paradigm to make coronary CT angiography (CCTA) accessible to allPredicting Mortality After Transcatheter Aortic Valve Replacement Using AI-Based Fully Automated Left Atrioventricular Coupling IndexPrediction of obstructive coronary artery disease using coronary calcification and epicardial adipose tissue assessments from CT calcium scoring scansSupport the show

>>Want more information like this? Sign up for Modern Endocrine's⁠⁠⁠⁠⁠⁠⁠⁠ ⁠newsletter https://linktr.ee/modernendocrine⁠⁠⁠⁠⁠⁠⁠⁠

Papilledema describes optic disc swelling (usually bilateral) arising from raised intracranial pressure. Due to its serious nature, there is a fear of underdiagnosis; hence, one major stumbling points is correct identification, which typically requires a thorough ocular examination including visual field testing. In this episode, Kait Nevel, MD speaks with Susan P. Mollan, MBChB, PhD, FRCOphth, author of the article “Papilledema” in the Continuum® April 2025 Neuro-ophthalmology issue. Dr. Nevel is a Continuum® Audio interviewer and a neurologist and neuro-oncologist at Indiana University School of Medicine in Indianapolis, Indiana. Dr. Mollan is a professor and neuro-ophthalmology consultant at University Hospitals Birmingham in Birmingham, United Kingdom. Additional Resources Read the article: Papilledema Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @IUneurodocmom Guest: @DrMollan Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Nevel: Hello, this is Dr Kait Nevel. Today I'm interviewing Dr Susan Mollan about her article Papilledema Diagnosis and Management, which appears in the April 2025 Continuum issue on neuro-ophthalmology. Susie, welcome to the podcast, and please introduce yourself to our audience. Dr Mollan: Thank you so much, Kait. It's a pleasure to be here today. I'm Susie Mollan, I'm a consultant neuro-ophthalmologist, and I work at University Hospitals Birmingham- and that's in England. Dr Nevel: Wonderful. So glad to be talking to you today about your article. To start us off, can you please share with us what you think is the most important takeaway from your article for the practicing neurologist? Dr Mollan: I think really the most important thing is about examining the fundus and actually trying to visualize the optic nerves. Because as neurologists, you're really acutely trained in examining the cranial nerves, and often people shy away from looking at the eyes. And it can give people such confidence when they're able to really work out straightaway whether there's going to be a problem or there's not going to be a problem with papilledema. And I guess maybe a little bit later on we can talk about the article and tips and tricks for looking at the fundus. But I think that would be my most important thing to take away. Dr Nevel: I'm so glad that you started with that because, you know, that's something that I find with trainees in general, that they often find one of the more daunting or challenging aspects of learning, really, how to do an excellent neurological exam is examining the fundus and feeling confident in diagnosing papilledema. What kind of advice do you give to trainees learning this skill? Dr Mollan: So, it really is practice and always carrying your ophthalmoscope with you. There's lots of different devices that people can choose to buy. But really, if you have a direct ophthalmoscope, get it out in the ward, get it out in clinic. Look at those patients that you'd know have alternative diagnosis, but it gives you that practice. I also invite everybody to come to the eye clinic because we have dilated patients there all the time. We have diabetic retinopathy clinics, and it makes it really easy to start to acquire those skills because I think it's very tricky, because you're getting a highly magnified view of the optic nerve and you've got to sort out in your head what you're actually looking at. I think it's practice. and then use every opportunity to really look at the fundus, and then ask your ophthalmology colleagues whether you can go to clinic. Dr Nevel: Wonderful advice. What do you think is most challenging about the evaluation of papilledema and why? Dr Mollan: I think there are many different aspects that are challenging, and these patients come from lots of different areas. They can come from the family doctor, they can come from an optician or another specialist. A lot of them can have headache. And, as you know, headache is almost ubiquitous in the population. So, trying to pull out the sort of salient symptoms that can go across so many different conditions. There's nothing that's pathognomonic for papilledema other than looking at the optic nerves. So, I think it's difficult because the presentation can be difficult. The actual history can be challenging. There are those rare patients that don't have headache, don't have pulsatile tinnitus, but can still have papilledema. So, I think it- the most challenging thing is actually confirming papilledema. And if you're not able to confirm it, getting that person to somebody who's able to help and confirm or refute papilledema is the most important thing. Dr Nevel: Yeah, right. Because you talk in your article the importance of distinguishing between papilledema and some other diagnoses that can look like papilledema but aren't papilledema. Can you talk about that a little bit? Dr Mollan: Absolutely. I think in the article it's quite nice because we were able to spend a bit of time on a big table going through all the pseudopapilledema diagnoses. So that includes people with shortsightedness, longsightedness, people with optic nerve head drusen. And we've been very fortunate in ophthalmology that we now have 3D imaging of the optic nerve. So, it makes it quite clear to us, when it's pseudopapilledema, it's almost unfair when you're using the direct ophthalmoscope that you don't get a cross sectional image through that optic nerve. So, I'd really sort of recommend people to delve into the article and look at that table because it nicely picks out how you could pick up pseudopapilledema versus papilledema. Dr Nevel: Perfect. In your article, you also talk about what's important to think about in terms of causes of papilledema and what to evaluate for. Can you tell us, you know, when you see someone who you diagnose with papilledema, what do you kind of run through in terms of diagnostic tests and things that you want to make sure you're evaluating for or not missing? Dr Mollan: Yeah. So, I think the first thing is, is once it's confirmed, is making sure it's isolated or whether there's any additional cranial nerve palsies. So that might be particularly important in terms of double vision and a sixth nerve palsy, but also not forgetting things like corneal sensation in the rest of the cranial nerves. I then make sure that we have a blood pressure. And that sounds a bit ridiculous in this day and age because everybody should have a blood pressure coming to clinic or into the emergency room. But sometimes it's overlooked in the panic of thinking, gosh, I need to investigate this person. And if you find that somebody does have malignant hypertension, often what we do is we kind of stop the investigational pathway and go down the route of getting the medics involved to help with lowering the blood pressure to a safe level. I would then always think about my next thing in terms of taking some bloods. I like to rule out anemia because anemia can coexist in a lot of different conditions of raised endocranial pressure. And so, taking some simple blood such as a complete blood count, checking the kidney function, I think is important in that investigational pathway. But you're not really going to stop there. You're going to move on to neuroimaging. It doesn't really matter what you do, whether you do a CT or an MRI, it's just getting that imaging pretty much on the same day as you see the patient. And the key point to that imaging is to do venography. And you want to rule out a venous sinus thrombosis cause that's the one thing that is really going to cause the patient a lot of morbidity. Once your neuroimaging is secure and you're happy, there's no structural lesion or a thrombosis, it's then reviewing that imaging to make sure it's safe to proceed with lumbar puncture. And so, we would recommend the lumbar puncture in the left lateral decubitus position and allowing the patient to be as calm and relaxed as possible to be able to get that accurate opening pressure. Once we get that, we can send the CSF for contents, looking for- making sure they don't have any signs of meningitis or raised protein. And then, really, we're at that point of saying, you know, we should have a secure diagnosis, whether it would be a structural lesion, venous sinus thrombosis, or idiopathic intracranial hypertension. Dr Nevel: Wonderful. Thank you for that really nice overview and, kind of, diagnostic pathway and stepwise thought process in the evaluations that we do. There are several different treatments for papilledema that you go through in your article, ranging from surgical to medication options. When we're taking care of an individual patient, what factors do you use to help guide you in this decision-making process of what treatment is best for the patient and how urgent treatment is? Dr Mollan: I think that's a really important question because there's two things to consider here. One is, what is the underlying diagnosis? Which, hopefully, through the investigational save, you'll have been able to achieve a secure diagnosis. But going along that investigational pathway, which determines the urgency of treatment, is, what's happening with the vision? If we have somebody where we're noting that the vision is affected- and normally it's actually through a formal visual field. And that's really challenging for lots of people to get in the emergency situation because syndromes of raised endocranial pressure often don't cause problems with the visual acuity or the color vision until it's very late. And also, you won't necessarily get a relative afferent papillary defect because often it's bilateral. So I really worry if any of those signs are there in somebody that may have papilledema. And so, a lot rests on that visual field. Now, we're quite good at doing confrontational visual fields, but I would say that most neurologists should be carrying pins to be able to look at the visual fields rather than just pointing fingers and quadrants if you're not able to get a formal visual field early. It's from that I would then determine if the vision is affected, I need to step up what I'm going to do. So, I think the sort of next thing to think about is that sort of vision. So, if we have somebody who, you know, you define as have severe sight loss at the point that you're going through this investigational pathway, you need to get an ophthalmologist or a neuro-ophthalmologist on board to help discuss either the surgery teams as to whether you need to be heading towards an intervention. And there are a number of different types of intervention. And the reason why we discuss it in the article---and we'll also be discussing it in a future issue of Continuum---is there's not high-class evidence to suggest one surgery over another surgery. We may touch on this later. So, we've got our patients with severe visual loss who we need to do something immediately. We may have people where the papilledema is moderate, but the vision isn't particularly affected. They may just have an enlarged blind spot. For those patients, I think we definitely need to be thinking about medical therapy and talking to them about what the underlying cause is. And the commonest medicine to use for raised endocranial pressure in this setting is acetazolamide, a carbonic anhydrous inhibitor. And I think that should be started at the point that you believe somebody has moderate papilledema, with a lot of discussion around the side effects of the medicine that we go into the article and also the fact that a lot of our patients find acetazolamide in an escalating dose challenging. There are some patients with very mild papilledema and no visual change where I might say, hey, I don't think we need to start treatment immediately, but you need to see somebody who understands your disease to talk to you about what's going on. And generally, I would try and get somebody out of the emergency investigational pathway and into a formal clinic as soon as possible. Dr Nevel: Thank you so much for that. One thing that I was wondering that we see clinically is you get a consult for a patient, maybe, who had an isolated episode of vertigo, back to their normal self, completely resolved… but incidentally, somebody ordered an MRI. And that MRI, in the report, it says partially empty sella, slight flattening of the posterior globe, concerns for increased intracranial pressure. What should we be doing with these patients who, you know, normal neurological exam, maybe we can't detect any definite papilledema on our endoscopic exam. What do you think the appropriate pathway is for those patients? Dr Mollan: I think it's really important. The more neuroimaging that we're doing, we're sort of seeing more people with signs that are we don't believe are normal. So, you've mentioned a few, the sort of partially empty sella, empty sella, tortuosity of the optic nerves, flattening of the globes, changes in transverse sinus. And we have quite a nice, again, table in the article that talks about these signs. But they have really low sensitivity for a diagnosis of raised endocranial pressure and isolation. And so, I think it's about understanding the context of which the neuroimaging has been taken, taking a history and going back and visiting that to make sure that they don't have escalating headache. And also, as you said, rechecking the eye nerves to make sure there's no papilledema. I think if you have a good examination with the direct ophthalmoscope and you determine that there's no papilledema, I would be confident to say there's no papilledema. So, I don't think they need to necessarily cry doubt. The ophthalmology offices, we certainly are having quite a few additional referrals, particularly for this, which we kind of called IIH-RAD, where patients are coming to us for this exclusion. And I think, in the intervening time, patients can get very anxious about having a sort of MRI artifact picked up that may necessarily mean a different diagnosis. So, I guess it's a little bit about reassurance, making sure we've taken the appropriate history and performed the examination. And then knowing that actually it's really a number of different signs that you need to be able to confidently diagnose raised ICP, and also the understanding that sometimes when people have these signs, if the ICP reduces, those signs remain. You know, we're learning an awful lot more about MRI imaging and what's normal, what's within normal limits. So, I think reassurance and sensible medical approach. Dr Nevel: Absolutely. In the section in your article on idiopathic intracranial hypertension, you spend a little bit of time talking about how important it is that we sensitively approach the topic of potential weight loss for those patients who are overweight. How do you approach that discussion in your clinic? Because I think it's an important part of the holistic patient care with that condition. Dr Mollan: I think this is one of the things that we've really listened to the patients about over the last number of years where we recognize that in an emergency situation, sometimes we can be quite quick to sort of say, hey, you have idiopathic endocranial hypertension and weight loss is, you know, the best treatment for the condition. And I think in those circumstances, it can be quite distressing to the patient because they feel that there's a lot of stigma attached around weight management. So, we worked with the patient group here at IIH UK to really come up with a way of a signposting to our patients that we have to be honest that there is a link, you know, a strong evidence that weight gain and body shape change can cause someone to fall into a diagnosis of IIH. And we know that weight loss is really effective with this condition. So, I think where I've learned from the patients is trying to use language that's less stigmatizing. I definitely signpost that I'm going to talk about something sensitive. So, I say I'm going to talk about something sensitive and I'm going to say, do you know that this condition is related to body shape change? And I know that if I listen to this podcast in a couple of years, I'm sure my words will have changed. And I think that's part of the process, is learning how to speak to people in an ever-changing language. And they think that sort of signpost that you're going to talk about something sensitive and you're going to talk about body shape change. And then follow up with, are you OK with me talking about this now? Is it something you want to talk about? And the vast majority of people say, yes, let's talk about it. There'll be a few people that don't want to talk about it. And I usually come in quite quickly, say, is it OK if I mention it at the next consultation? Because we have a duty of care to sort of inform our patients, but at the same time we need to take them on that journey to get them back to health, and they need to be really enlisted in that process. Dr Nevel: Yeah, I really appreciate that. These can be really difficult conversations and uncomfortable conversations to have that are really important. And you're right, we have a duty as medical providers to have these conversations or inform our patients, but the way that we approach it can really impact the way patients perceive not only their diagnosis, but the relationship that we have with our patients. And we always want that to be a positive relationship moving forward so that we can best serve our patients. Dr Mollan: I think the other thing as well is making sure that you've got good signposts to the professionals. And that's what I say, because people then say to me, well, you know, kind of what diet should I be on? What should I be doing? And I say, well, actually, I don't have professional experience with that. I'm, I'm very fortunate in my hospital, I'm able to send patients to the endocrine weight management service. I'm also able to send patients to the dietetic service. So, it's finding, really, what suits the patient. Also what's within licensing in your healthcare system to be able to provide. But not being too prescriptive, because when you spend time with weight management professionals, they'll tell you lots of different things about diets that people have championed and actually, in randomized controlled trials, they haven't been effective. I think it's that signpost really. Dr Nevel: Yeah, absolutely. So, could you talk a little bit about what's going on in research in papilledema or in this area, and what do you think is up-and-coming? Dr Mollan: I think there's so much going on. Mainly there's two parts of it. One is image analysis, and we've had some really fantastic work out of the Singapore group Bonsai looking at a machine learning decision support tool. When people take fundal pictures from a normal fundus camera, they're able to say with good certainty, is this papilledema, is this not papilledema? But more importantly, if you talk to the investigators, something that we can't tell when we look in is they're able to, with quite a high level of certainty, say, well, this is base occupying lesion, this is a venous sinus thrombosis, and this is IIH. And you know, I've looked at thousands and thousands of people's eyes and that I can't tell why that is. So, I think the area of research that is most exciting, that will help us all, is this idea about decision support tools. Where, in your emergency pathway, you're putting a fundal camera in that helps you be able to run the image, the retina, and also to try and work out possibly what's going on. I think that's where the future will go. I think we've got many sort of regulatory steps and validation and appropriate location of a learning to go on in that area. So, that's one side of the imaging. I think the other side that I'm really excited about, particularly with some of the work that we've been doing in Birmingham, is about treatment. The surgical treatments, as I talked about earlier… really, there's no high-class evidence. There's a number of different groups that have been trying to do randomized trials, looking at stenting versus shunting. They're so difficult to recruit to in terms of trials. And so, looking at other treatments that can reduce intracranial pressure. We published a small phase two study looking at exenatide, which is a glucagon-like peptide receptor agonist, and it showed in a small group of patients living with IIH that it could reduce the intracranial pressure two and a half hours, twenty-four hours, and also out to three months. And the reason why this is exciting is we would have a really good acute therapy---if it's proven in Phase III trials---for other diseases, so, traumatic brain injury where you have problems controlling ICP. And to be able to do that medically would be a huge breakthrough, I think, for patient care. Dr Nevel: Yeah, really exciting. Looking forward to seeing what comes in the future then. Wonderful. Well, thank you so much for chatting with me today about your article. I really enjoyed learning more from you during our conversation today and from your article, which I encourage all of our listeners to please read. Lots of good information in that article. So again, today I've been interviewing Dr Susie Mollan about her article Papilledema Diagnosis and Management, which appears in the most recent issue of Continuum on neuro-ophthalmology.Please be sure to check out Continuum episodes from this and other issues. And thank you to our listeners for joining us today. Thank you, Susie. Dr Mollan: Thank you so much. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

This episode of the World Shared Practice Forum Podcast dives into the origins and objectives of the Acute Care Action Network (ACAN), led by Dr. Lee Wallis at the World Health Organization. Discover how ACAN aims to integrate emergency, critical, and operative care to enhance healthcare systems globally, focusing on universal health coverage and preparedness for health emergencies. Dr. Wallis shares insights into the challenges posed by the COVID-19 pandemic, the establishment of ACAN, and its ambitious goals in the face of funding constraints. This episode is essential for healthcare professionals eager to understand global healthcare strategies and improve acute care delivery. LEARNING OBJECTIVES - Explain the role and mission of the Acute Care Action Network (ACAN) within the WHO - Identify the impact of the COVID-19 pandemic on global healthcare systems and emergency care - Discuss the five operational priorities set by ACAN for strengthening acute care - Describe ACAN's strategic partnership goals and membership framework - Analyze how integrated emergency care can improve healthcare preparedness and response AUTHORS Lee Wallis, MBChB, PhD, PhD (hon), Dip IMC RCS Edin, Dip Sport Med, FRCS Edin, FRCP Edin, FRCEM, FCEM(SA), FEMSSA, FIFEM Lead, Emergency & Critical Care World Health Organization Jeffery Burns, MD, MPH Emeritus Chief Division of Critical Care Medicine Department of Anesthesiology, Critical Care and Pain Medicine Boston Children's Hospital Professor of Anesthesia Harvard Medical School DATE Initial publication date: April 21, 2025. TRANSCRIPT https://cdn.bfldr.com/D6LGWP8S/at/39b93qf5q67b237gxtpv5wf/042125_WSP_Wallis_Transcript.pdf Please visit: http://www.openpediatrics.org OPENPediatrics™ is an interactive digital learning platform for healthcare clinicians sponsored by Boston Children's Hospital and in collaboration with the World Federation of Pediatric Intensive and Critical Care Societies. It is designed to promote the exchange of knowledge between healthcare providers around the world caring for critically ill children in all resource settings. The content includes internationally recognized experts teaching the full range of topics on the care of critically ill children. All content is peer-reviewed and open-access thus at no expense to the user. For further information on how to enroll, please email: openpediatrics@childrens.harvard.edu CITATION Wallis L, Burns JP. Enhancing Global Acute Care: Understanding the WHO's ACAN. 04/2025. OPENPediatrics. Online Podcast. https://soundcloud.com/openpediatrics/enhancing-global-acute-care-understanding-the-whos-acan-by-l-wallis-openpediatrics.

In this episode, Chloe Orkin, MBChB, FRCP, MD, and Jean-Michel Molina, MD, PhD, discuss highlights from CCO's independent conference coverage of CROI 2025, including:Advances in HIV treatment based on results from CARESPotential HIV therapies in the pipeline, such as doravirine/islatravirEffects of broadly neutralizing antibodies on HIV treatment and cure Key clinical data on HIV and STI prevention obtained from PILLAR, HPTN 083, PURPOSE 1, and STOMPPresenters:Chloe Orkin, MBChB, FRCP, MDProfessor of Infection and InequitiesDean for Healthcare TransformationHonorary Consultant Physician, Barts Health NHS TrustFaculty of Medicine and DentistryQueen Mary University of LondonLondon, United KingdomJean-Michel Molina, MD, PhDProfessor of MedicineUniversity of Paris CiteDepartment of Infectious DiseasesSaint-Louis and Lariboisiere Hospitals, APHPParis, FranceLink to full program:bit.ly/3E1bAYQTo access all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. 

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/RFR865. CME credit will be available until March 27, 2026.Adopting Modern Management Strategies for Obesity: Treating the Patient, Not the Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/RFR865. CME credit will be available until March 27, 2026.Adopting Modern Management Strategies for Obesity: Treating the Patient, Not the Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/RFR865. CME credit will be available until March 27, 2026.Adopting Modern Management Strategies for Obesity: Treating the Patient, Not the Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/RFR865. CME credit will be available until March 27, 2026.Adopting Modern Management Strategies for Obesity: Treating the Patient, Not the Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/RFR865. CME credit will be available until March 27, 2026.Adopting Modern Management Strategies for Obesity: Treating the Patient, Not the Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/RFR865. CME credit will be available until March 27, 2026.Adopting Modern Management Strategies for Obesity: Treating the Patient, Not the Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/RFR865. CME credit will be available until March 27, 2026.Adopting Modern Management Strategies for Obesity: Treating the Patient, Not the Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/RFR865. CME credit will be available until March 27, 2026.Adopting Modern Management Strategies for Obesity: Treating the Patient, Not the Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

In this episode of Pushing the Limits, we dive deep into female hormone health with Dr. Samantha Newman, founder of Female GP. Whether you're in your 20s or navigating menopause, hormones play a crucial role in energy, mood, metabolism, fertility, and overall well-being. Dr. Newman shares her holistic and medical approach to hormone optimisation, helping women achieve hormonal balance through functional medicine, lifestyle, nutrition, and biohacking strategies. Topics Covered: The biggest hormonal imbalances affecting women today The role of stress, sleep, and nutrition in hormone health How to optimise your hormones The impact of perimenopause and menopause on energy, weight, and mood Bioidentical hormones and natural supplements for hormonal balance How to get your doctor to work with you on your hormone journey  The importance of understanding your hormone history to understand where you are at today. If you're struggling with PMS, low energy, mood swings, brain fog, weight gain, or burnout, this episode is packed with actionable insights to help you take control of your hormonal health. Subscribe & share if you know someone who needs this info! Dr. Samantha Newman Bio: Dr. Samantha Newman, MBChB, BSc (hons), PGDipOMG, General Practitioner with a Specialist Interest in Women's Health | Honorary Lecturer at the University of Auckland | Adjunct Associate Researcher University of Monash Dr Samantha runs a specialist women's health clinic and works as a GP at a Family Practice. Her practice is founded upon empowering women to understand their body and mind, and how pelvic, musculoskeletal, brain and hormone health are inseparable. Dr Sam is involved in research projects, is a founder and trustee of women's health charity, Rose Gold Trust, and has a passion for educating.

Guest host Paul Whiting, MD chats with 2024 OTA Humanitarian Scholars Mohamed Fathy Elkhosousy, MD, and Marcella Ryan-Coker, MBChB, MSc, Mmed. Live from the 2024 OTA Annual Meeting. For additional educational resources visit OTA.org  

Kevin Fernando, MBChB, BSC Hons (Med Sci), MSc Diabetes - The Many Faces of PBC: Recognising Opportunities to Optimise Identification and Intervention Across Diverse Patient Populations

Kevin Fernando, MBChB, BSC Hons (Med Sci), MSc Diabetes - The Many Faces of PBC: Recognising Opportunities to Optimise Identification and Intervention Across Diverse Patient Populations

Join hosts Nidhi Madan, MD; Prashant Nagpal, MD, FSCCT; Jill Jacobs, MD, MS-HQSM, FSCCT and Cristina Fuss, MD, PhD, FSCCT as they take a deep dive into featured articles in the November – December 2024 issue of the Journal of Cardiovascular Computed Tomography (JCCT). Our hosts chat with Michelle Williams, MBChB, PhD, FSCCT; Maria Hauge, MD and Takayuki Niida, MD. This episode will explore:Artificial Intelligence and Machine Learning for Cardiovascular Computed Tomography (CCT): A White Paper of the Society of Cardiovascular Computed Tomography (SCCT) Aortic dimensions in women with previous pre-eclampsia Differences in total plaque burden between plaque rupture and plaque erosion: A combined computed tomography angiography and optical coherence tomography study Support the show

Ian SD Roberts, MBChB, FRCPath / Joris Roelofs, MD, PhD - Best Practices in Renal Pathology: Avoiding Common Pitfalls in the Diagnostic Pathways for Glomerular Diseases

Ian SD Roberts, MBChB, FRCPath / Joris Roelofs, MD, PhD - Best Practices in Renal Pathology: Avoiding Common Pitfalls in the Diagnostic Pathways for Glomerular Diseases

Ian SD Roberts, MBChB, FRCPath / Joris Roelofs, MD, PhD - Best Practices in Renal Pathology: Avoiding Common Pitfalls in the Diagnostic Pathways for Glomerular Diseases

Who knew that the Duke's criteria could be further modified? In Part 2, Vin and Ruan continue discussing infective endocarditis with the help of skilled cardiologist, Dr Raaesah Bhorat, this time discussing treatment: empiric, targeted and surgical therapy.About our Guest: Dr Raeesa Bhorat is a cardiologist at Sunninghill hospital, working as an interventional fellow under Professor Hellig. She completed her cardiology training at Groote Schuur hospital in 2024; and her interests include structural intervention and research in the application of artificial intelligence to cardiology, particularly the electrocardiogram. She completed her fellowship in internal medicine in 2019 and received her MBChB degree in 2013, cum laude.WE'D LOVE YOUR FEEDBACK ON THIS EPISODE – Visit the Microbe Mail website to sign up for updates Follow on:Instagram: Microbe_MailX/Twitter: @microbemailFacebook: MicrobeMailTiktok: @microbe.mailWatch this episode on our new YouTube channel: Microbe MailE-mail us: mail.microbe@gmail.com

Who knew that the Duke's criteria could be further modified? In this episode, Vin and Ruan explore this update to the criterion and other critical aspects of diagnosing and managing infective endocarditis with the help of skilled cardiologist, Dr Raaesah Bhorat.About our Guest: Dr Raaesah Bhorat is a cardiologist at Sunninghill hospital, working as an interventional fellow under Professor Hellig. She completed her cardiology training at Groote Schuur hospital in 2024; and her interests include structural intervention and research in the application of artificial intelligence to cardiology, particularly the electrocardiogram. She completed her fellowship in internal medicine in 2019 and received her MBChB degree in 2013, cum laudeWE'D LOVE YOUR FEEDBACK ON THIS EPISODE – Visit the Microbe Mail website to sign up for updates Follow on:Instagram: Microbe_MailX/Twitter: @microbemailFacebook: MicrobeMailTiktok: @microbe.mailWatch this episode on our new YouTube channel: Microbe MailE-mail us: mail.microbe@gmail.com

Paul Wheatley-Price, BSc, MBChB, MD, FRCP (UK) / Parneet K. Cheema, MD - Addressing Key Challenges to Improve Outcomes in Patients With NSCLC With Rare Actionable Genomic Alterations

In this World Shared Practice Forum podcast, Dr. Mark Peters discusses the Oxy-PICU trial, published in The Lancet in January 2024, which compared conservative to liberal oxygenation targets in critically ill children. The study highlighted the importance of pragmatic trial design and the need for larger trials to confirm these findings. LEARNING OBJECTIVES -Discuss the background driving the investigation of oxygenation in critically ill children -Summarize the study design of the Oxy-PICU Trial -Present the outcomes and challenges of the Oxy-PICU Trial -Identify the key characteristics of pragmatic trial design and the implication of pragmatic trial results AUTHORS Mark Peters, MBChB, MRCP, FFICM, FRCPCH, PhD Professor of Paediatric Intensive Care NIHR Senior Investigator UCL Great Ormond St Institute of Child Health Hon. Consultant Paediatric Intensivist Paediatric Intensive Care Unit and Children's Acute Transport Service Great Ormond St Hospital Jeffrey Burns, MD, MPH Emeritus Chief Division of Critical Care Medicine Department of Anesthesiology, Critical Care and Pain Medicine Boston Children's Hospital Professor of Anesthesia Harvard Medical School DATE Initial publication date: November 26, 2024. ARTICLES REFERENCED AND ADDITIONAL RESOURCES Peters MJ, Gould DW, Ray S, et al. Conservative versus liberal oxygenation targets in critically ill children (Oxy-PICU): a UK multicentre, open, parallel-group, randomised clinical trial [published correction appears in Lancet. 2024 Jan 27;403(10424):354. doi: 10.1016/S0140-6736(24)00100-4]. Lancet. 2024;403(10424):355-364. https://pubmed.ncbi.nlm.nih.gov/38048787/ Fan E, Del Sorbo L, Goligher EC, et al. An Official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: Mechanical Ventilation in Adult Patients with Acute Respiratory Distress Syndrome [published correction appears in Am J Respir Crit Care Med. 2017 Jun 1;195(11):1540. doi: 10.1164/rccm.19511erratum]. Am J Respir Crit Care Med. 2017;195(9):1253-1263. https://pubmed.ncbi.nlm.nih.gov/28459336/ Peters MJ, Ramnarayan P. Randomized Trials to Reduce Clinical Uncertainty: Gold Standard or Fool's Gold? Pediatr Crit Care Med. 2024;25(8):775-777. https://pubmed.ncbi.nlm.nih.gov/39101806/ Darnell R, Brown A, Laing E, et al. Protocol for a Randomized Controlled Trial to Evaluate a Permissive Blood Pressure Target Versus Usual Care in Critically Ill Children with Hypotension (PRESSURE). Pediatr Crit Care Med. 2024;25(7):629-637. https://pubmed.ncbi.nlm.nih.gov/38629915/ Taccone FS, Rynkowski Bittencourt C, Møller K, et al. Restrictive vs Liberal Transfusion Strategy in Patients With Acute Brain Injury: The TRAIN Randomized Clinical Trial. JAMA.Published online October 09, 2024. https://pubmed.ncbi.nlm.nih.gov/39382241/ Jones GAL, Eaton S, Orford M, et al. Randomization to a Liberal Versus Conservative Oxygenation Target: Redox Responses in Critically Ill Children. Pediatr Crit Care Med. 2023;24(3):e137-e146. https://pubmed.ncbi.nlm.nih.gov/36728001/ UK-ROX: https://www.icnarc.org/research-studies/uk-rox/ MegaROX: https://www.anzics.org/current-active-endorsed-research/mega-rox/ ICU-ROX: https://www.thebottomline.org.uk/summaries/icm/icu-rox/ TRANSCRIPT https://cdn.bfldr.com/D6LGWP8S/as/rq7kgwqkh4hk4nk67584pfj/202411_-_WSP_-_Less_is_more_Oxygenation_Targets_in_Critically_Ill_Children_-_Transcript?position=2 CITATION Peters MJ, Burns JP. Less is More: Oxygenation Targets in Critically Ill Children. 11/2024. OPENPediatrics. https://soundcloud.com/openpediatrics/less-is-more-oxygenation-targets-in-critically-ill-children-by-m-peters-openpediatrics.

Ffion Davies, MBChB, FRCPCH, FRCEM - Managing Major Bleeding in Patients Receiving DOACs: Data, Developments, and Decision-Making in the ED

Ffion Davies, MBChB, FRCPCH, FRCEM - Managing Major Bleeding in Patients Receiving DOACs: Data, Developments, and Decision-Making in the ED

Ffion Davies, MBChB, FRCPCH, FRCEM - Managing Major Bleeding in Patients Receiving DOACs: Data, Developments, and Decision-Making in the ED

In this rapid webinar, Meredith E. Clement, MD, and Linda-Gail Bekker, MBChB, DTMH, DCH, FCP(SA), PhD, provide an overview of important topics and studies presented at HIVR4P 2024, including:Expanding PrEP options based on results from PURPOSE 2, IMPOWER-22, IMPOWER-24, IPM 054, MTN-025/HOPE OLE, CATALYST, and the HPTN 084 substudyImplementing injectable PrEP based on results from PEPFAR, the USAID DISCOVER-Health LA CAB Demonstration Project in Zambia, and the LA CAB PrEP Rapid Start Model in Public Health ClinicsImproving PrEP uptake based on results from SPrEP and HPTN 091  Presenters:Meredith E. Clement, MDAssociate ProfessorInfectious DiseasesLouisiana State University Health Sciences CenterNew Orleans, LouisianaLinda-Gail Bekker, MBChB, DTMH, DCH, FCP(SA), PhDDirector and Professor, The Desmond Tutu HIV Centre, UCTCEO, The Desmond Tutu Health FoundationCape Town, South AfricaTo access all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Link to full program: https://bit.ly/3NJIDSA

In this rapid webinar, Meredith E. Clement, MD, and Linda-Gail Bekker, MBChB, DTMH, DCH, FCP(SA), PhD, provide an overview of important topics and studies presented at HIVR4P 2024, including:Expanding PrEP options based on results from PURPOSE 2, IMPOWER-22, IMPOWER-24, IPM 054, MTN-025/HOPE OLE, CATALYST, and the HPTN 084 substudyImplementing injectable PrEP based on results from PEPFAR, the USAID DISCOVER-Health LA CAB Demonstration Project in Zambia, and the LA CAB PrEP Rapid Start Model in Public Health ClinicsImproving PrEP uptake based on results from SPrEP and HPTN 091 Presenters:Meredith E. Clement, MDAssociate ProfessorInfectious DiseasesLouisiana State University Health Sciences CenterNew Orleans, LouisianaLinda-Gail Bekker, MBChB, DTMH, DCH, FCP(SA), PhDDirector and Professor, The Desmond Tutu HIV Centre, UCTCEO, The Desmond Tutu Health FoundationCape Town, South AfricaTo access all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Link to full program: https://bit.ly/3NJIDSA

Leading health care professionals Edwina A. Brown, MD, MBChB, Timothy Ray, CNN, CNN-NP, DNP, NP, and Monnie Wasse, MD, MPH, FASN, share their perspectives on evolving advances in dialysis treatments and patient care in the US and across the globe.

Leading health care professionals Edwina A. Brown, MD, MBChB, Timothy Ray, CNN, CNN-NP, DNP, NP, and Monnie Wasse, MD, MPH, FASN, share their perspectives on evolving advances in dialysis treatments and patient care in the US and across the globe.

Americans say there is no place for the likes of McDonald's and Chick-fil-A in hospitals.   The giants of fast food are serving greasy, fatty, artery-clogging foods in the same building where patients are receiving artery-opening stents and pacemakers. Often these lifesaving surgeries are just a floor or two above where the unhealthy combo meals are being served up.   In a way it's like having an Alcoholics Anonymous meeting above a bar. It just doesn't make sense.   Eating fast food four times a week may increase heart disease risk by 80%, according to one study.   So, why is it happening?   Dr. Roxanne Becker joins "The Weight Loss Champion" Chuck Carroll on The Exam Room Podcast to talk about the findings of the hospital survey that revealed mounting frustrations with the state of hospital food.   — — SHOW LINKS — — Hospital Fast Food Survey Background: https://bit.ly/PCRMHospitalFoodSurvey Full survey: https://bit.ly/FastFoodHospitals2024 — — — Roxanne Becker, MBChB, DipIBLM Bio: https://www.pcrm.org/about-us/staff/roxanne-becker — — — Free Athlete Nutrition E-Book https://www.pcrm.org/athlete — — BECOME AN EXAM ROOM VIP — — Sign up: https://www.pcrm.org/examroomvip — — THIS IS US — — The Exam Room Podcast Instagram: https://www.instagram.com/theexamroompodcast — — — Chuck Carroll Instagram: https://www.instagram.com/ChuckCarrollWLC Facebook: http://wghtloss.cc/ChuckFacebook X: https://www.twitter.com/ChuckCarrollWLC — — — Physicians Committee Instagram: https://www.instagram.com/physicianscommittee Facebook: https://www.facebook.com/PCRM.org X: https://www.twitter.com/pcrm YouTube: https://www.youtube.com/user/PCRM Jobs: https://www.pcrm.org/careers — — SUBSCRIBE & SHARE — — 5-Star Success: Share Your Story Apple: https://apple.co/2JXBkpy​​ Spotify: https://spoti.fi/2pMLoY3 Please subscribe and give the show a 5-star rating on Apple Podcasts, Spotify, or many other podcast providers. Don't forget to share it with a friend for inspiration!

In July, Ruan braved the AIDS-related Mycoses workshop held in Cape Town as the lone Microbe messenger. He attended sessions where speakers discussed novel findings in the epidemiology, prevention, diagnosis and therapy for some of the deadliest fungal infections globally. In this episode he and Vin take through some of the brief discussions he had with some of the enlightening researchers. Meet our Guests: Dr Juan Louis Rodriguez Tudela MD, PhDDr Michail Lionakis, M.D., Sc.D.Dr Felix Bongomin, M.D., MScProf Alessandro Pasqualotto, Professor of Infectious Diseases, with special interest in medical mycology and Fellow of the European Confederation of Medical Mycology. Dr Trevor Mnguni, MBChB, FCP(SA), Cert Pulm(SA)Prof Joseph Jarvis, Consultant Physician and Epidemiologist at Botswana-UPenn Partnership and Honorary Senior Lecturer, LSHTMWE'D LOVE YOUR FEEDBACK ON THIS EPISODE – Visit the Microbe Mail website to sign up for updates Follow on:Instagram: Microbe_MailX/Twitter: @microbemailFacebook: MicrobeMailTiktok: @microbe.mailWatch this episode on our new YouTube channel: Microbe MailE-mail us: mail.microbe@gmail.com

In this episode, Matt speaks with Dr Keith Scott-Mumby. Dr Keith Scott-Mumby is a medical professional who transitioned into alternative healing and pioneered the exploration of food allergy phenomena. With an MBChB degree (equivalent to an MD), he established one of the world's first alternative allergy clinics and made legal history by linking food allergies to violent behaviour. Dr. Scott-Mumby has been a leading figure in alternative medicine, focusing on energetic medicine and anti-aging science.Dr Keith and Matt discuss:Dr Keith's journey from medical training to recognising the connection between food and health.The origins of food allergies and intolerances.The prevalence of the above and how to discover our own personal food bandits.The impact of these food bandits which rob us off our health and vitalityHow to start listening to your bodies signal's to discover which foods are robbing you of healthWant to connect with Dr Keith or learn more? Check out the links below:Email - keith.scottmumby@gmail.comInstagram: @keithscottmumbyWebsite - http://www.alternative-doctor.com/For questions or to work with Matt, you can reach him via:Email: info@wellnesseducationdubai.comWebsite: Wellness Education DubaiInstagram: @wellness_education_dubaiFacebook: Matt Marney FitnessLinkedIn: Matt Marney (Wellness Education Dubai)

Deborah Siegal, MD, MSc, FRCPC / Richard Body, MBChB, FRCEM, PhD - Turn the Bleed Around: Expert Perspectives on the Evolving Evidence for Management of Factor Xa Inhibitor-Associated Life-Threatening Bleeding

Deborah Siegal, MD, MSc, FRCPC / Richard Body, MBChB, FRCEM, PhD - Turn the Bleed Around: Expert Perspectives on the Evolving Evidence for Management of Factor Xa Inhibitor-Associated Life-Threatening Bleeding

Precision medicine — the approach to health care that involves tailoring medical interventions to an individual's genetic makeup, environment and lifestyle — promises to deliver the right treatment to the right person at the right time. From preventing diseases decades before they appear, to specially designed cocktails of cancer drugs, to genetic modification of rare diseases, many of these applications sound straight out of science fiction. At the forefront of precision medicine and medical genomics is Euan Ashley, MBChB, DPhill, Chair of Medicine at Stanford University Medical Center. A cardiologist and intensive care physician by training, Dr. Ashley has pioneered the use of genetic sequencing to identify risk factors for heart disease and new treatments for rare diseases. He is also the author of The Genome Odyssey: Medical Mysteries and the Incredible Quest to Solve Them (2021).Over the course of our conversation, we discuss his path from growing up in a small Scottish town to now working at the cutting edge of medicine, the excitement and fulfillment he experiences as a clinician in the cardiac intensive care unit, remarkable patient stories of healing and resilience, the future of precision medicine, why he is optimistic about the development of artificial intelligence, and more.In this episode, you'll hear about: 2:24 - Dr. Ashley's path to medicine and to cardiology 7:19 - What life is like working in the CCU21:34 - How the Undiagnosed Diseases Network was founded and what it does33:22 - An overview of precision medicine38:09 - The impact that genetic testing and genomic medicine is having on modern medicine and where it could go from here 45:00 - Dr. Ashley's thoughts on how AI will change the field of medicine 51:40 - Making access to medical advancements in AI and genomics more equitable 1:04:39 - Dr. Ashley's advice for healthcare professionals in training Dr. Euan Ashley can be found on Twitter/X at @euanashley. Visit our website www.TheDoctorsArt.com where you can find transcripts of all episodes.If you enjoyed this episode, please subscribe, rate, and review our show, available for free on Spotify, Apple Podcasts, or wherever you get your podcasts. If you know of a doctor, patient, or anyone working in health care who would love to explore meaning in medicine with us on the show, feel free to leave a suggestion in the comments or send an email to info@thedoctorsart.com.Copyright The Doctor's Art Podcast 2024

Quarraisha Abdool Karim, PhD, and Salim S. Abdool Karim, MBChB, PhD, are the recipients of the 2024 Lasker-Bloomberg Public Service Award for their decades of work on AIDS in Africa. The infectious diseases epidemiologists recently reflected on their life's work in a conversation with JAMA Deputy Editor and infectious diseases physician Preeti Malani, MD, MSJ. Related Content: Thirty-Five Years of HIV Research in Africa—An Interview With Winners of the 2024 Lasker-Bloomberg Public Service Award AIDS in Africa—Impact of Research

Want to send us a message? Fan mail? Thoughts on the episode?Dr Nils Bergman calls himself a Public Health Physician, and currently promotes and researches skin-to- skin contact on a full time basis. He is a Research Associate at the Karolinska Institute, Sweden. Dr. Bergman was born in Sweden and raised in Zimbabwe, where he also later worked as a mission doctor. He received his medical degree (MB ChB) at the University of Cape Town, a Diploma in Child Health at Uppsala University, and later a Masters in Public Health at the University of the Western Cape. During his years in Zimbabwe he completed a doctoral dissertation (MD, equivalent to PhD) on deadly scorpion stings. He has worked in South Africa, Zimbabwe and Sweden, and his last posting was Senior Medical Superintendent of Mowbray Maternity Hospital in Cape Town, overseeing 18000 births per year. He is married to Jill, and father to Rebecka, Simon and Emma, and has five grandchildren.In this episode, Dr. Bergman delves into the critical importance of maintaining skin-to-skin contact throughout the first day of a newborn's life. He explains how this practice not only connects and wires the baby's brain but also has profound effects on the mother.Dr. Bergman sheds light on the pivotal role of Oxytocin, often dubbed the 'love hormone,' which he eloquently describes as the hormone of resilience, vital for both mother and baby.We further explore the crucial significance of focusing not only on the first 1000 days of a child's life but also on the first 1000 minutes. Dr. Bergman passionately explains how these early moments are foundational for long-term health and emotional resilience.Additionally, we dive into the detailed work behind the latest version of the WHO Kangaroo Mother Care (KMC) document. Dr. Bergman shares insights into the creation of this and introduces us to the concept of 'nurture-science.' He discusses how this emerWant to listen to the new podcast 'The Feeding Couch'? Find it here or on all good podcast hosting platforms! Get 10% off Katie's Breastfeeding & Lactation: the fundamentals online course today with code POD10 at checkout. Support the Show. Please support the show via Patreon or BuyMeACoffee MERCH here! Music Joseph McDade Like this podcast? Leave us a review here Want more from Katie and Rachel? Katie's website Rachel's website DisclaimerThe information provided on this podcast does not, and is not intended to, constitute medical or legal advice; instead, all information available on this site are for general informational purposes only. The Midwives' Cauldron podcast reserves the right to supplement, change or delete any information at any time.The information and materials on the podcast is provided "as is"; no representations are made that the content is error-free. Whilst we have tried to ensure the accuracy and completeness of the information we do not warrant or guarantee the accurateness. The podcast accepts no liability for any loss or damage howsoever arising out of the use or reliance on the content.

"Learning POCUS, Part 2: Training for Anesthesiologists and Our Future Generations" by Calah Myhre, MS2, Vivian Ip, MBChB, MRCP, FRCA, and Hari Kalagara, MD. From ASRA Pain Medicine News, May 2024. See original article at www.asra.com/may24news for figures and references. This material is copyrighted. Support the Show.

In this episode, Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD, uses a case study to illustrate why patients living with HIV may disengage with their care and how best to reengage them once they present at the clinic, including discussion of:The valid reasons patients have for disengaging with their HIV careWhy the return to care should be celebratedHow to support people living with HIV as they reengage in careHow to prevent future loss to follow-upPresenter:Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhDCEO, Desmond Tutu Health FoundationDirector, Desmond Tutu HIV CentreProfessor of MedicineFaculty of Health SciencesUniversity of Cape TownCape Town, South AfricaContent based on an online CME program supported by an educational grant from Gilead Sciences, Inc.Link to full program:https://bit.ly/3xicSeFGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts or Spotify.

"Plastic in Healthcare: Everywhere and Hidden in Plain Sight" by Deirdre C. Kelleher, MD, E.B. Fouts-Palmer, MD, and Vivian Ip, MBChB, MRCP, FRCA. From ASRA Pain Medicine News, May 2024. See original article at www.asra.com/may24news for figures and references. This material is copyrighted. Support the Show.

In this Complex Care Journal Club podcast episode, Dr. Lorna Fraser discusses the results of a prospective cohort study comparing outcomes for children receiving home blends vs formula via gastrostomy tube. She describes the central role of patients and families in study design, opportunities for ensuring equitable access to blended diets, and next steps from this work. SPEAKER Lorna Fraser, PhD, MBChB, MRCPCH, MSc, MMedSci Professor of Palliative Care and Child Health, Cicely Saunders Institute and School of Life Sciences and Population Health King's College London HOST Kathleen Huth, MD, MMSc Pediatrician, Complex Care Service, Division of General Pediatrics Boston Children's Hospital Assistant Professor of Pediatrics Harvard Medical School DATES Initial Publication date: April 8, 2024 JOURNAL ARTICLES Journal Club Article Citations Fraser LK, Bedendo A, O'Neill M, Taylor J, Hackett J, Horridge KA, Cade J, Richardson G, Phung H, McCarter A, Hewitt CE. Safety, resource use and nutritional content of home-blended diets in children who are gastrostomy fed: Findings from 'YourTube' - a prospective cohort study. Arch Dis Child. 2023 Dec 21:archdischild-2023-326393. doi: 10.1136/archdischild-2023-326393. Fraser LK, Bedendo A, O'Neill M, Taylor J, Hackett J, Horridge K, Cade J, Richardson G, Phung H, Mccarter A, Hewitt C. 'YourTube' the role of different diets in gastrostomy-fed children: Baseline findings from a prospective cohort study. Dev Med Child Neurol. 2023 Nov 10. doi: 10.1111/dmcn.15799. OTHER REFERENCES Hron B, Fishman E, Lurie M, Clarke T, Chin Z, Hester L, Burch E, Rosen R. Health Outcomes and Quality of Life Indices of Children Receiving Blenderized Feeds via Enteral Tube. J Pediatr. 2019 Aug;211:139-145.e1. doi: 10.1016/j.jpeds.2019.04.023. Epub 2019 May 23. PMID: 31128885; PMCID: PMC6660979. Maddison J, Taylor J, O'Neill M, Cade J, Hewitt C, Horridge K, McCarter A, Fraser LK, Beresford B. Outcomes for gastrostomy-fed children and their parents: qualitative findings from the 'Your Tube' study. Dev Med Child Neurol. 2021 Sep;63(9):1099-1106. doi: 10.1111/dmcn.14868. Epub 2021 Apr 1. PMID: 33792913. University of York. YourTube: Home blended diets for children who are gastrostomy fed. Infographic. Accessed March 13, 2024. https://www.york.ac.uk/media/healthsciences/images/research/phs/mhrc/Yourtube%20-%200102%20Infographic%20print.pdf University of York. YourTube for parent/healthcare professional. YouTube. January 19, 2024. Accessed March 13, 2024. https://youtu.be/5POi2Cjp8og University of York. YourTube for young people. YouTube. January 19, 2024. Accessed March 13, 2024. https://youtu.be/NlVriI0O-oI TRANSCRIPT chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://op-docebo-images.s3.amazonaws.com/Transcripts/Building+the+Evidence+for+Blended+Diets_Fraser_040824.pdf Clinicians across healthcare professions, advocates, researchers, and patients/families are all encouraged to engage and provide feedback! You can recommend an article for discussion using this form: https://forms.gle/Bdxb86Sw5qq1uFhW6 Please visit: http://www.openpediatrics.org OPENPediatrics™ is an interactive digital learning platform for healthcare clinicians sponsored by Boston Children's Hospital and in collaboration with the World Federation of Pediatric Intensive and Critical Care Societies. It is designed to promote the exchange of knowledge between healthcare providers around the world caring for critically ill children in all resource settings. The content includes internationally recognized experts teaching the full range of topics on the care of critically ill children. All content is peer-reviewed and open access-and thus at no expense to the user.For further information on how to enroll, please email: openpediatrics@childrens.harvard.edu CITATION Fraser L, Huth K. Building the Evidence for Blended Diets: Benefits and Barriers to Access. 4/2024. OPENPediatrics. Online Podcast. https://on.soundcloud.com/pcQSrJTHvF4H4yiY6